Skip to content
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter
Main Menu
  • News
  • Insights
  • Interviews
  • Reports
  • Newsletter

About Me

Nick Mars - Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis. Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Social Icons

Facebook1,750FansLikeX (Twitter)759FollowersFollowInstagram2,500FollowersFollowPinterest1,365FollowersPinYoutube2,700SubscribersSubscribeTiktok2,900FollowersFollowTelegram2,000MembersJoinSoundcloud1,963FollowersFollowVimeo1,254FollowersFollowDribbble3,520FollowersFollow
  • Support
    • Documentation
    • Documentation
    • Video Tutorials
    • Video Tutorials
    • Support Forums
    • Support
  • Support
  • About Theme
  • About theme
  • Visit Us
  • Visit Us
Wednesday, June 24, 2026
Home / cancer care therapeutics

Browsing Tag: cancer care therapeutics

  • Commercial
  • News
  • Regulatory

Organon & Henlius Launch BILDYOS and TUZEMTY in Canada 

Takeaways:  The new products expand Organon’s Canadian biosimilars line to eight drugs across five therapeutic areas, including oncology, strengthening its position as a major biosimilar sup...

Arisa Smith
June 24, 2026
Read More

Social Icons

Facebook1,000FansLikeX (Twitter)1,000FollowersFollowInstagram1,000FollowersFollowPinterest1,000FollowersPinYoutube1,000SubscribersSubscribeTiktok1,000FollowersFollowTelegram1,000MembersJoinSoundcloud1,000FollowersFollowVimeo1,000FollowersFollowDribbble1,000FollowersFollow

Featured Posts

1
AbbVie’s Boey Approved in Canada for Glabellar Lines 
June 24, 2026
2
Roche’s Itovebi Moves Closer to Public Access in Canada 
June 24, 2026
3
Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 
June 24, 2026
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Minima incidunt voluptates nemo, dolor optio quia architecto quis delectus perspiciatis.

Nobis atque id hic neque possimus voluptatum voluptatibus tenetur, perspiciatis consequuntur.

Email: sample@gmail.com
Call Us: +987 95 95 64 82

Category List

  • Commercial(11)
  • Companies(13)
  • Deals(5)
  • Editor's Pick(5)
  • Latest Updates(1)
  • Manufacturing(6)
  • Must Read(4)
  • News(66)
  • Opinions(30)
  • Public Health(10)
  • R&D(12)
  • Regulatory(38)
  • Technology(8)

Featured Posts

1
AbbVie’s Boey Approved in Canada for Glabellar Lines 
June 24, 2026
2
Roche’s Itovebi Moves Closer to Public Access in Canada 
June 24, 2026
3
Takeda’s Zasocitinib Beats Deucravacitinib in Psoriasis Phase 3 Trial 
June 24, 2026
Copyright © 2026 | Powered by News Magazine X